The drug company Corbus Pharmaceuticals will start its next Phase 2 clinical trial to test a potential inflammation-targeting drug in people with cystic fibrosis in the first quarter of 2018.
Site Search
Showing 1 - 10 of 33 results
News
|
May 6, 2011
|
1 min read
News
|
Jan. 30, 2018
|
3 min read
Icagen Inc. will focus on drug discovery, screening for compounds that could suppress nonsense mutations, and using computer modeling to identify molecules that are suitable to be developed into drugs.
News
|
May 1, 2018
|
2 min read
News
|
Sept. 16, 2008
|
1 min read
News
|
March 11, 2009
|
1 min read
News
|
Feb. 7, 2007
|
1 min read
News
|
March 19, 2007
|
2 min read
Infections are caused by tiny organisms. All germs have one thing in common: When they find a place that is good for them to live, they set up a home for themselves and multiply.
This week, Congress approved a budget resolution that will allow lawmakers to make certain changes to the Affordable Care Act and Medicaid.
News
|
Dec. 12, 2017
|
1 min read
Today, the Cystic Fibrosis Foundation announced that it will invest up to $8.4 million in SpliSense's Series B funding round to develop an antisense oligonucleotide therapy for people with cystic fibrosis who have splicing mutations and potentially other rare mutations.
News
|
May 13, 2021
|
4 min read